Small molecule inhibitors of STAT3 for cancer therapy

Current Medicinal Chemistry

Volumn 18, Issue 26, 2011, Pages 4012-4018

  Zhao, M ^a   Jiang, B ^a   Gao, F H ^a  

^a No 3 People's Hospital   (China)

Author keywords

Antitumor therapeutics; Molecular targeted therapy; Signal transducer and activator of transcription 3; Small molecule inhibitors

Indexed keywords

ANTINEOPLASTIC AGENT; CISPLATIN; CPA 1; CPA 7; CPC 188; CPC 3; CPC 30; FLLL 31; FLLL 32; GALIELLALACTONE; IS 3295; ISS 610; LLL 12; LLL 3; S3I 201; STA 21; STAT3 PROTEIN; STATTIC; STX 0119; UNCLASSIFIED DRUG;

ANGIOGENESIS; DRUG MECHANISM; DRUG TARGETING; GENE INDUCTION; HUMAN; MOLECULAR WEIGHT; MOLECULARLY TARGETED THERAPY; NONHUMAN; REVIEW; STRUCTURE ACTIVITY RELATION; TUMOR ESCAPE;

ANIMALS; CELL LINE, TUMOR; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MICE; MOLECULAR TARGETED THERAPY; NEOPLASMS; SIGNAL TRANSDUCTION; SMALL MOLECULE LIBRARIES; STAT3 TRANSCRIPTION FACTOR;

EID: 80052197203     PISSN: 09298673     EISSN: 1875533X     Source Type: Journal    
DOI: 10.2174/092986711796957284     Document Type: Review

References (55)

1. Akira, S.; Nishio, Y.; Inoue, M.; Wang, X.J.; Wei, S.; Matsusaka, T.; Yoshida, K.; Sudo, T.; Naruto, M.; Kishimoto, T. Molecular cloning of APRF, a novel IFN-stimulated gene factor 3 p91-related transcription factor involved in the gp130-mediated signaling pathway. Cell, 1994, 77(1), 63-71.
2. Song, H.; Wang, R.; Wang, S.; Lin, J. A low-molecular-weight compound discovered through virtual database screening inhibits Stat3 function in breast cancer cells. Proc. Natl. Acad. Sci. U S A., 2005, 102(13), 4700-4705. (Pubitemid 40471517)
3. Kluge, A.; Dabir, S.; Kern, J.; Nethery, D.; Halmos, B.; Ma, P.; Dowlati, A. Cooperative interaction between protein inhibitor of activated signal transducer and activator of transcription-3 with epidermal growth factor receptor blockade in lung cancer. Int. J. Cancer., 2009, 125(7), 1728-1734.
4. Minegishi, Y.; Saito, M.; Tsuchiya, S.; Tsuge, I.; Takada, H.; Hara, T.; Kawamura, N.; Ariga, T.; Pasic, S.; Stojkovic, O.; Metin, A.; Karasuyama, H. Dominant-negative mutations in the DNA-binding domain of STAT3 cause hyper-IgE syndrome. Nature, 2007, 448(7157), 1058-1062. (Pubitemid 47345590)
5. Kunigal, S.; Lakka, S.S.; Sodadasu, P.K.; Estes, N.; Rao, J.S. Stat3-siRNA induces Fas-mediated apoptosis in vitro and in vivo in breast cancer. Int. J. Oncol., 2009, 34(5), 1209-1220.
6. Klosek, S.K.; Nakashiro, K.; Hara, S.; Goda, H.; Hamakawa, H. Stat3 as a molecular target in RNA interference-based treatment of oral squamous cell carcinoma. Oncol. Rep., 2008, 20(4), 873-878.
7. Yu, H.; Jove, R. The STATs of cancer-new molecular targets come of age. Nat. Rev. Cancer, 2004, 4(2), 97-105. (Pubitemid 38198738)
8. Siddiquee, K.; Zhang, S.; Guida, W.C.; Blaskovich, M.A.; Greedy, B.; Lawrence, H.R.; Yip, M.L.; Jove, R.; McLaughlin, M.M.; Lawrence, N.J.; Sebti, S.M.; Turkson, J. Selective chemical probe inhibitor of Stat3, identified through structure-based virtual screening, induces antitumor activity. Proc. Natl. Acad. Sci. U S A., 2007, 104(18), 7391-7396. (Pubitemid 47185916)
9. Siddiquee, K.A.; Gunning, P.T.; Glenn, M.; Katt, W.P.; Zhang, S.; Schrock, C.; Sebti, S.M.; Jove, R.; Hamilton, A.D.; Turkson, J. An oxazole-based small-molecule Stat3 inhibitor modulates Stat3 stability and processing and induces antitumor cell effects. ACS. Chem. Biol., 2007, 2(12), 787-798. (Pubitemid 351166054)
10. Jing, N.; Zhu, Q.; Yuan, P.; Li, Y.; Mao, L.; Tweardy, D.J. Targeting signal transducer and activator of transcription 3 with G-quartet oligonucleotides: a potential novel therapy for head and neck cancer. Mol. Cancer Ther., 2006, 5(2), 279-286.
11. Weerasinghe, P.; Garcia, G.E.; Zhu, Q.; Yuan, P.; Feng, L.; Mao, L.; Jing, N. Inhibition of Stat3 activation and tumor growth suppression of non-small cell lung cancer by G-quartet oligonucleotides. Int. J. Oncol., 2007, 31(1), 129-136.
12. Al Zaid Siddiquee, K.; Turkson, J. STAT3 as a target for inducing apoptosis in solid and hematological tumors. Cell Res., 2008, 18(2), 254-267. (Pubitemid 351206162)
13. Ren, Z.; Mao, X.; Mertens, C.; Krishnaraj, R.; Qin, J.; Mandal, P.K.; Romanowski, M.J.; McMurray, J.S.; Chen, X. Crystal structure of unphosphorylated STAT3 core fragment. Biochem. Biophys. Res. Commun., 2008, 374(1), 1-5.
14. Huang, S. Regulation of metastases by signal transducer and activator of transcription 3 signaling pathway: clinical implications. Clin. Cancer Res., 2007, 13(5), 1362-1366. (Pubitemid 46450423)
15. Levy, D.E.; Darnell, J.E., Jr. Stats: transcriptional control and biological impact. Nat. Rev. Mol. Cell Biol., 2002, 3(9), 651-662. (Pubitemid 34987786)
16. Turkson, J.; Kim, J.S.; Zhang, S.; Yuan, J.; Huang, M.; Glenn, M.; Haura, E.; Sebti, S.; Hamilton, A.D.; Jove, R. Novel peptidomimetic inhibitors of signal transducer and activator of transcription 3 dimerization and biological activity. Mol. Cancer Ther., 2004, 3(3), 261-269. (Pubitemid 39193701)
17. Bromberg, J. Stat proteins and oncogenesis. J. Clin. Invest., 2002, 109(9), 1139-1142. (Pubitemid 34496590)
18. Shuai, K. The STAT family of proteins in cytokine signaling. Prog. Biophys. Mol. Biol., 1999, 71(3-4), 405-422. (Pubitemid 29156310)
19. Klampfer, L. The role of signal transducers and activators of transcription in colon cancer. Front. Biosci., 2008, 13, 2888-2899. (Pubitemid 351589205)
20. Turkson, J. STAT proteins as novel targets for cancer drug discovery. Expert. Opin.Ther. Targets., 2004, 8(5), 409-422. (Pubitemid 39359648)
21. Pandey, M.K.; Sung, B.; Ahn, K.S.; Aggarwal, B.B. Butein suppresses constitutive and inducible signal transducer and activator of transcription (STAT) 3 activation and STAT3-regulated gene products through the induction of a protein tyrosine phosphatase SHP-1. Mol. Pharmacol., 2009, 75(3), 525-533.
22. Benekli, M.; Baumann, H.; Wetzler, M. Targeting signal transducer and activator of transcription signaling pathway in leukemias. J. Clin. Oncol., 2009, 27(26), 4422-4432.
23. Behera, R.; Kumar, V.; Lohite, K.; Karnik, S.; Kundu, G.C. Activation of JAK2/STAT3 signaling by osteopontin promotes tumor growth in human breast cancer cells. Carcinogenesis, 2010, 31(2), 192-200.
24. Leeman, R.J.; Lui, V.W.; Grandis, J.R. STAT3 as a therapeutic target in head and neck cancer. Expert. Opin. Biol. Ther., 2006, 6(3), 231-241. (Pubitemid 43344743)
25. Nikitakis, N.G.; Siavash, H.; Sauk, J.J. Targeting the STAT pathway in head and neck cancer: recent advances and future prospects. Curr. Cancer Drug Targets, 2004, 4(8), 637-651. (Pubitemid 40013571)
26. Kortylewski, M.; Jove, R.; Yu, H. Targeting STAT3 affects melanoma on multiple fronts. Cancer Metastasis Rev., 2005, 24(2), 315-327. (Pubitemid 40922802)
27. He, M.; Young, C.Y. New approaches to target the androgen receptor and STAT3 for prostate cancer treatments. Mini. Rev. Med. Chem., 2009, 9(3), 395-400.
28. Xie, K.; Wei, D.; Huang, S. Transcriptional anti-angiogenesis therapy of human pancreatic cancer. Cytokine Growth Factor Rev., 2006, 17(3), 147-156. (Pubitemid 43816895)
29. Weidler, M.; Rether, J.; Anke, T.; Erkel, G. Inhibition of interleukin-6 signaling by galiellalactone. FEBS. Lett., 2000, 484(1), 1-6.
30. Hellsten, R.; Johansson, M.; Dahlman, A.; Dizeyi, N.; Sterner, O.; Bjartell, A. Galiellalactone is a novel therapeutic candidate against hormonerefractory prostate cancer expressing activated Stat3. Prostate, 2008, 68(3), 269-280. (Pubitemid 351273056)
31. Kopcke, B.; Weber, R.W.; Anke, H. Galiellalactone and its biogenetic precursors as chemotaxonomic markers of the Sarcosomataceae (Ascomycota). Phytochemistry, 2002, 60(7), 709-714. (Pubitemid 34857122)
32. Sun, J.; Blaskovich, M.A.; Jove, R.; Livingston, S.K.; Coppola, D.; Sebti, S.M. Cucurbitacin Q: a selective STAT3 activation inhibitor with potent antitumor activity. Oncogene, 2005, 24(20), 3236-3245. (Pubitemid 40695105)
33. Turkson, J.; Zhang, S.; Mora, L.B.; Burns, A.; Sebti, S.; Jove, R. A novel platinum compound inhibits constitutive Stat3 signaling and induces cell cycle arrest and apoptosis of malignant cells. J. Biol. Chem., 2005, 280(38), 32979-32988. (Pubitemid 41368347)
34. Turkson, J.; Zhang, S.; Palmer, J.; Kay, H.; Stanko, J.; Mora, L.B.; Sebti, S.; Yu, H.; Jove, R. Inhibition of constitutive signal transducer and activator of transcription 3 activation by novel platinum complexes with potent antitumor activity. Mol. Cancer. Ther., 2004, 3(12), 1533-1542. (Pubitemid 40136708)
35. Turkson, J.; Ryan, D.; Kim, J.S.; Zhang, Y.; Chen, Z.; Haura, E.; Laudano, A.; Sebti, S.; Hamilton, A.D.; Jove, R. Phosphotyrosyl peptides block Stat3-mediated DNA binding activity, gene regulation, and cell transformation. J. Biol. Chem., 2001, 276(48), 45443-45455.
36. Ren, Z.; Cabell, L.A.; Schaefer, T.S.; McMurray, J.S. Identification of a high-affinity phosphopeptide inhibitor of Stat3. Bioorg. Med. Chem. Lett., 2003, 13(4), 633-636. (Pubitemid 36298456)
37. Mann, M.J.; Dzau, V.J. Therapeutic applications of transcription factor decoy oligonucleotides. J. Clin. Invest., 2000, 106(9), 1071-1075.
38. Morishita, R.; Tomita, N.; Kaneda, Y.; Ogihara, T. Molecular therapy to inhibit NFkappaB activation by transcription factor decoy oligonucleotides. Curr. Opin. Pharmacol., 2004, 4(2), 139-146. (Pubitemid 38444048)
39. Zhang, X.; Zhang, J.; Wei, H.; Tian, Z. STAT3-decoy oligodeoxynucleotide inhibits the growth of human lung cancer via down-regulating its target genes. Oncol. Rep., 2007, 17(6), 1377-1382.
40. Liu, X.; Li, J.; Zhang, J. STAT3-decoy ODN inhibits cytokine autocrine of murine tumor cells. Cell. Mol. Immunol., 2007, 4(4), 309-313.
41. Leong, P.L.; Andrews, G.A.; Johnson, D.E.; Dyer, K.F.; Xi, S.; Mai, J.C.; Robbins, P.D.; Gadiparthi, S.; Burke, N.A.; Watkins, S.F.; Grandis, J.R. Targeted inhibition of Stat3 with a decoy oligonucleotide abrogates head and neck cancer cell growth. Proc. Natl. Acad. Sci. U S A., 2003, 100(7), 4138-4143. (Pubitemid 36418170)
42. Bhasin, D.; Cisek, K.; Pandharkar, T.; Regan, N.; Li, C.; Pandit, B.; Lin, J.; Li, P.K. Design, synthesis, and studies of small molecule STAT3 inhibitors. Bioorg. Med. Chem. Lett., 2008, 18(1), 391-395.
43. Chen, C.L.; Loy, A.; Cen, L.; Chan, C.; Hsieh, F.C.; Cheng, G.; Wu, B.; Qualman, S.J.; Kunisada, K.; Yamauchi-Takihara, K.; Lin, J. Signal transducer and activator of transcription 3 is involved in cell growth and survival of human rhabdomyosarcoma and osteosarcoma cells. BMC. Cancer., 2007, 7, 111.
44. Fuh, B.; Sobo, M.; Cen, L.; Josiah, D.; Hutzen, B.; Cisek, K.; Bhasin, D.; Regan, N.; Lin, L.; Chan, C.; Caldas, H.; DeAngelis, S.; Li, C.; Li, P.K.; Lin, J. LLL-3 inhibits STAT3 activity, suppresses glioblastoma cell growth and prolongs survival in a mouse glioblastoma model. Br. J. Cancer., 2009, 100(1), 106-112.
45. Mencalha, A.L.; Du Rocher, B.; Salles, D.; Binato, R.; Abdelhay, E. LLL-3, a STAT3 inhibitor, represses BCR-ABL-positive cell proliferation, activates apoptosis and improves the effects of Imatinib mesylate. Cancer Chemother. Pharmacol., 2010, 65(6), 1039-1046.
46. Lin, L.; Hutzen, B.; Li, P.K.; Ball, S.; Zuo, M.; DeAngelis, S.; Foust, E.; Sobo, M.; Friedman, L.; Bhasin, D.; Cen, L.; Li, C.; Lin, J. A novel small molecule, LLL12, inhibits STAT3 phosphorylation and activities and exhibits potent growth-suppressive activity in human cancer cells. Neoplasia, 2010, 12(1), 39-50.
47. Pang, M.; Ma, L.; Gong, R.; Tolbert, E.; Mao, H.; Ponnusamy, M.; Chin, Y.E.; Yan, H.; Dworkin, L.D.; Zhuang, S. A novel STAT3 inhibitor, S3I-201, attenuates renal interstitial fibroblast activation and interstitial fibrosis in obstructive nephropathy. Kidney Int., 2010, 78(3), 257-268.
48. Zhang, X.; Yue, P.; Fletcher, S.; Zhao, W.; Gunning, P.T.; Turkson, J. A novel small-molecule disrupts Stat3 SH2 domain-phosphotyrosine interactions and Stat3-dependent tumor processes. Biochem. Pharmacol., 2010, 79(10), 1398-1409.
49. Schust, J.; Sperl, B.; Hollis, A.; Mayer, T.U.; Berg, T. Stattic: a smallmolecule inhibitor of STAT3 activation and dimerization. Chem. Biol., 2006, 13(11), 1235-1242. (Pubitemid 44750735)
50. Lin, L.; Hutzen, B.; Zuo, M.; Ball, S.; Deangelis, S.; Foust, E.; Pandit, B.; Ihnat, M.A.; Shenoy, S.S.; Kulp, S.; Li, P.K.; Li, C.; Fuchs, J.; Lin, J. Novel STAT3 phosphorylation inhibitors exhibit potent growth-suppressive activity in pancreatic and breast cancer cells. Cancer Res., 2010, 70(6), 2445-2454.
51. Yue, P.; Turkson, J. Targeting STAT3 in cancer: how successful are we? Expert. Opin. Investig. Drugs., 2009, 18(1), 45-56.
52. Ge, J.; Wu, H.; Yao, S.Q. An unnatural amino acid that mimics phosphotyrosine. Chem. Commun (Camb)., 2010, 46(17), 2980-2982.
53. Becker, S.; Groner, B.; Muller, C.W. Three-dimensional structure of the Stat3beta homodimer bound to DNA. Nature, 1998, 394(6689), 145-151. (Pubitemid 28325960)
54. Xu, X.; Kasembeli, M.M.; Jiang, X.; Tweardy, B.J.; Tweardy, D.J. Chemical probes that competitively and selectively inhibit Stat3 activation. PLoS. One., 2009, 4(3), e4783.
55. Timofeeva, O.A.; Gaponenko, V.; Lockett, S.J.; Tarasov, S.G.; Jiang, S.; Michejda, C.J.; Perantoni, A.O.; Tarasova, N.I. Rationally designed inhibitors identify STAT3 N-domain as a promising anticancer drug target. ACS. Chem. Biol., 2007, 2(12), 799-809. (Pubitemid 351166055)